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The role of apparent diffusion coefficient (ADC) in the diagnosis of breast cancer and 
its association with molecular biomarkers was investigated in 259 patients with breast 
cancer, 67 with benign pathology, and 54 healthy volunteers using diffusion-weighted 
imaging (DWI) at 1.5 T. In 59 breast cancer patients, dynamic contrast-enhanced MRI 
(DCEMRI) was also acquired. Mean ADC of malignant lesions was significantly lower 
(1.02 ± 0.17 × 10−3 mm2/s) compared to benign (1.57 ± 0.26 × 10−3 mm2/s) and healthy 
(1.78 ± 0.13 × 10−3 mm2/s) breast tissues. A cutoff ADC value of 1.23 × 10−3 mm2/s 
(sensitivity 92.5%; specificity 91.1%; area under the curve 0.96) to differentiate malig-
nant from benign diseases was arrived by receiver operating curve analysis. In 10/59 
breast cancer patients, indeterminate DCE curve was seen, while their ADC value was 
indicative of malignancy, implying the potential of the addition of DWI in increasing the 
specificity of DCEMRI data. Further, the association of ADC with tumor volume, stage, 
hormonal receptors [estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor (HER2)], and menopausal status was investigated. A significant 
difference was seen in tumor volume between breast cancer patients of stages IIA and 
IIIA, IIB and IIIA, and IIB and III (B + C), respectively (P < 0.05). Patients with early breast 
cancer (n = 52) had significantly lower ADC and tumor volume than those with locally 
advanced breast cancer (n = 207). No association was found in ADC and tumor volume 
with the menopausal status. Breast cancers with ER−, PR−, and triple-negative (TN) 
status showed a significantly larger tumor volume compared to ER+, PR+, and non- 
triple-negative (nTN) cancers, respectively. Also, TN tumors showed a significantly higher 
ADC compared to ER+, PR+, and nTN cancers. Patients with ER− and TN cancers 
were younger than those with ER+ and nTN cancers. The present study demonstrated 
that ADC may increase the diagnostic specificity of DCEMRI and be useful for treatment 
management in clinical setting. Additionally, it provides an insight into characterization of 
molecular types of breast cancer and may serve as an indicator of metabolic reprogram-
ing underlying tumor proliferation.
Keywords: diffusion-weighted Mri, breast cancer, apparent diffusion coefficient, benign lesions, molecular 
biomarkers, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2
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inTrODUcTiOn
Breast cancer is a heterogeneous tumor exhibiting five molecu-
lar types, classified by gene profiling and the expression of hor-
monal receptors such as estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor (HER2) (1). 
The pre-operative tumor size nodal status metastasis (TNM) 
stage, tumor grade, receptor status, lymph node status, and 
Ki-67 were outcome predictors of breast cancer in previous 
studies (2, 3). Accordingly, early diagnosis of malignancy in 
individual patients may be important for a successful therapy. 
Mammography is the primary diagnostic screening tool, despite 
its limitation in sensitivity and specificity, especially in regard 
to the dense breast (4, 5). In such cases, ultrasound is useful. 
However, it has limitations in detecting microcalcification and 
ductal carcinoma in situ (DCIS) (6). Breast magnetic resonance 
imaging (MRI) has become an important adjunct modality in 
the evaluation of suspicious mammographically occult breast 
lesions, detection of tumor recurrence, and screening of 
women with high-risk cancer and those with breast implants 
(7). It is also useful in pre-operative tumor staging and in the 
assessment of post-therapy residual disease in a clinical set-
ting (7). The use of dynamic contrast-enhanced (DCE) MRI 
with gadolinium-based contrast agents depicts high-resolution 
tumor morphology and allows for contrast uptake kinetics, 
tumor angiogenesis, and vascularity (8). The DCEMRI has 
been shown to have high sensitivity (93–99%) but with variable 
specificity (37–85%) (9).
The rapid proliferation of cancer is associated with repro-
graming both the anabolic and catabolic pathways, supporting 
its growth and altering the intracellular and extracellular milieu. 
Functional MR imaging technique – such as diffusion-weighted 
imaging (DWI) –  is useful to monitor such changes associated 
with tumor proliferation (10–12). By measuring diffusion con-
stant of water molecules, DWI provides information about the 
extracellular and intracellular tissue compartments as well as the 
altered pathologies during cancer growth. The presence of cell 
membranes, macromolecules, and organelles restrict the motion 
of water molecules, and therefore decreases the diffusion constant 
of water compared to free aqueous solution. This is represented 
as apparent diffusion coefficient (ADC) (13). ADC has been used 
in differentiating various tissue pathologies, and DWI has in fact 
been established as an important adjunct technique with many 
clinical applications (10, 14). Studies have documented a relation-
ship between the cell density and ADC (12, 15). Applications of 
DWI include characterization of malignant, benign, and healthy 
breast tissues (12, 16–18), and monitoring of the therapeutic 
response of breast tumors (19, 20). A correlation of ADC with the 
histological features and the enhancement ratios using DCEMRI 
has been reported (21). The growth patterns of cancer and the 
architectural features of stroma using DWI (21) and the correla-
tion between ADC with the molecular markers of breast cancer 
have been reported (22–26). The addition of DWI increases the 
specificity of DCEMRI (27).
The objectives of the present study were (a) to determine a 
cutoff value of ADC for the differentiation of malignant, benign, 
and healthy breast tissues in a large cohort of subjects; (b) to 
evaluate the potential of quantitative DWI in differentiating 
various histological types of malignant and benign lesions; (c) to 
evaluate the potential of ADC in indeterminate DCEMRI find-
ings in a sub-group of patients; and (d) to examine the associa-
tion of ADC, stage, tumor volume, age, menopausal status, and 
hormonal receptors in these patients.
PaTienTs anD MeThODs
Patients
In this prospective study, a total of 388 subjects, including 259 with 
breast malignancy, 67 with benign breast pathology attending the 
breast cancer clinic of our Institute, and 54 healthy volunteers, 
were recruited during the period of 2007–2015. However, data 
of 8 subjects [malignant (n =  4), benign (n =  2), and healthy 
volunteers (n  =  2)] were excluded from analyses because of 
motion and other artifacts. The demographic and histological 
details were presented in Table 1. American Joint Committee on 
Cancer (AJCC) TNM criteria were used for clinical staging of 
patients, which included stage IIA, IIB, IIIA, and IIIB +  C. In 
breast cancer patients, MR was performed prior to therapy with at 
least 1 week after the core biopsy. The purpose and the methodol-
ogy of the study were fully explained to all the subjects. All studies 
were carried out as per the standard regulatory guidelines of the 
institute ethics committee, which approved the study, and writ-
ten informed consent was obtained from each subject. Clinical 
history and physical examination was taken for all patients. An 
ultrasonography, mammogram [Breast imaging Reporting and 
Data System (BIRADS) IV and V lesions], and histology (fine 
needle aspiration cytology/core biopsy) were performed. All 
patients had clinically palpable lumps, and the size of tumor was 
measured in two dimensions using a Vernier caliper after palpa-
tion. In this study, there were no patients with non-subcutaneous 
tumors.
Biopsied tissues were subjected to histology and immuno-
histochemical examinations to determine the expression of 
hormonal receptors, such as ER, PR, and HER2, status according 
to the standard published guidelines by the American Society 
of Clinical Oncology/College of American Pathologists (28). 
Patients with HER2 expression scores of 0 and 1+ were catego-
rized as HER2 negative (HER2−) and those with the scores of 
3+ were categorized as HER2 positive (HER2+). Patients with 
a score of 2+ were excluded from the analysis since their data of 
fluorescence in situ hybridization were not available. Accordingly, 
the ER status was available for 185 patients, PR status for 182, and 
HER2 status for 144 patients, and other details were presented in 
Table 1.
All patients underwent metastatic workup as per the standard 
guidelines for clinical staging of the tumor prior to any interven-
tional procedure such as neoadjuvant chemotherapy (NACT) or 
surgery. Further, the metastatic workup included liver function 
tests, chest roentgenogram, and ultrasound evaluation of abdo-
men, pelvis, and bone scan. Patients with metastasis, atypia, 
claustrophobic, on prior treatment, radial scar, pregnant, using 
contraceptive pills, metallic implants, pacemaker, etc., and also 
those not willing to take part in the study, were excluded.
TaBle 1 | Demographic details of subjects.
Breast cancer (n = 259)
Age in years [mean ± SD (range)] 45.4 ± 10.5 (19–70)
aHistology type
number
Invasive ductal carcinoma (IDC) 182
IDC with ductal carcinoma in situ (DCIS) 8
IDC + mucinous carcinoma 6
DCIS + cribriform type 2
Papillary carcinoma 1
Ductal adenocarcinoma 2
Lobular carcinoma 3
Medullary carcinoma 1
Neuroendocrine tumor 1
Malignant phyllodes 1
Pagets disease 1
Fibrous stroma 1
AJCC stage
IIA 52
IIB 49
IIIA 45
III (B + C) 113
Hormone receptor status
ER+ 93
ER− 92
PR+ 82
PR− 100
HER2+ 56
HER2− 84
HER2 2+ 23
Triple negative (TN) 26
Non-triple negative (nTN) 155
Triple positive (TP) 13
Benign lesions (n = 67)
Age in years [mean ± SD (range)] 30 ± 9.4 (13–61)
Histology type
number
Fibroadenoma 33
Phyllodes 8
Benign ductal epithelial cells 8
Fibrocystic fibroadenoma 8
Cysts 6
Benign proliferative breast disease 1
Fibroepithelial lesion 1
Sclerosing adenosis 1
Mastitis 1
healthy volunteers (n = 54)
Age in years [mean ± SD (range)] 30 ± 9.4 (13–61)
aHistopathology available for 209 breast cancer patients only.
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Mr imaging
MR imaging was performed using a four-channel-phased array 
breast matrix receiver coil at 1.5 T (Magnetom AVANTO, Siemens 
Healthcare Sector, Germany). Subjects were positioned with head 
first in prone position with each breast fitting into the cup of the 
coil. Following the scout images, short tau inversion recovery 
coronal images were acquired with repetition time (TR) and time 
to echo (TE) of 6940 and 58 ms, respectively; slice thickness of 
3 mm; and a matrix size of 320 × 256. Also, fat-suppressed MR 
images were acquired in transverse and sagittal planes (TR and 
TE of 6270 and 102 ms, respectively; slice thickness = 3 mm with 
no gap; matrix size =  512 ×  440). DCEMRI in the axial plane 
was carried out for 59 breast cancer patients using a fat-saturated 
3D FLASH (fast low angle shot) sequence with the following 
parameters: TR and TE of 5.46 and 2.53  ms, respectively; flip 
angle = 12°; matrix size = 305 × 448; and slice thickness = 1.4 mm 
with no gap. Gadolinium-diethylene triamine pentaacetic acid 
(Gd-DTPA) contrast agent (0.1  mmol/kg) was injected using 
automatic injector at a rate of 2 ml/s followed by saline flush. One 
pre- followed by five post-gadolinium image series were acquired 
with a total acquisition time of 5.5 min (6 × 55 s).
Diffusion-weighted imaging sequence calibration was carried 
out using a single compartment phantom for water and acetone 
prepared in separate containers. The mean ADC for water and 
acetone were 2.25 ± 0.03 × 10−3 and 4.1 ± 0.17 × 10−3 mm2/s, 
respectively, which were in agreement with the literature (12). 
Reproducibility of ADC measurements were checked with 
repeated measurements, and the coefficient of variance (COV) 
were within 1 and 4% of error limit for water and acetone, respec-
tively. DW images were acquired in the transverse plane covering 
both the breasts using a single shot echo-planar imaging sequence 
with the diffusion gradients applied along the orthogonal direc-
tion concurrently to reduce motion artifacts (10). The parameters 
used for DWI were b = 0, 500, and 1000 s/mm2; TR = 5000 ms; 
TE = 87 ms; FOV = 250–350 mm; NSA = 1; EPI factor = 128; 
acquisition matrix = 128 × 128; and slice thickness = 4–5 mm 
without any inter slice gap. The total acquisition time was 42 s. 
A minimum of two b values are necessary for the measurement 
of ADC; however, the curve fitting with more than two b values 
reduces the error in ADC estimation by linear regression method; 
hence, DWI scan with three b values was acquired.
aDc Measurement
Mean ADC values were calculated using an ADC map and by 
drawing contiguous circular ROIs of five pixels (size = 0.49 cm2) 
on the lesion (malignant and benign lesions) from each patient 
and from the entire healthy breast tissue in volunteers. For ADC 
calculation, the mean number of ROIs used for malignant cases 
was 20 (range 2–137), 19 (range 2–75) for benign cases, and 36 
(range 8–163) for healthy volunteers.
Tumor Volume Measurement
The tumor volume was measured from MR images by a perim-
eter method using the formula: volume = ST (A1 + A2, …, An), 
where ST is the slice thickness and A is the area of the tumor 
(20). The subtracted axial dynamic images were used for volume 
calculation, while sagittal (T2 fat-saturated) images were used in 
patients for whom DCEMRI could not be carried out. All slices 
(with no inter slice gap) in which the tumor was seen were used 
for volume calculation using free hand ROIs. In six malignant 
lesions of infiltrating ductal carcinoma (IDC) type, ROIs were 
drawn twice to find out intra-individual variation, which was 
later verified by another co-author (Uma Sharma). The difference 
between the COV of the two measurements (inter-individual) 
was 0.001, and 95% confidence intervals of the difference (CI) 
was −1.633 to −1.341, indicating that there was no significant 
variation between the two measurements. The inter-observer 
agreement was assessed using intraclass correlation coefficient 
(ICC). The ICC was 0.99, indicating better reproducibility of 
volume measurements by two different observers.
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statistical analysis
One-way analysis of variance (ANOVA) followed by Bonferroni 
post  hoc correction was used for comparisons of mean ADC 
among malignant, benign, and healthy breast tissues. Further, 
comparison of mean ADC values was also carried out using the 
analysis of covariance (ANCOVA), considering age as a covariate 
since mean age was significantly different among the three groups. 
Receiver operating curve (ROC) analysis was used to obtain cutoff 
values of mean ADC for the differentiation of malignant, benign, 
and healthy breast tissues. The sensitivity and specificity of ADC 
were also calculated. Student’s t-test was used to compare the age 
(years), mean ADC, and tumor volume between patients with 
positive and negative hormonal receptor status. ANOVA with 
Bonferroni post hoc correction was used for comparisons of mean 
ADC and tumor volume among various tumor stages. A P-value 
of ≤0.05 was considered significant. All statistical analyses were 
carried out using statistical software SPSS 19.0.
resUlTs
Figure 1 shows the T2-weighted MR image of (A) a 28-year-old 
patient with IDC; (B) a 25-year-old patient with benign fibroad-
enoma; and (C) that from a 30-year-old normal healthy volunteer. 
The DWI images obtained for malignant, benign, and healthy 
breast tissues are shown in Figures 1D–F, while the respective 
ADC maps obtained are shown in Figures 1G–I. Figure 2A shows 
the representative DCE image of a 56-year-old locally advanced 
breast cancer (LABC) patient with IDC, and the corresponding 
Type III curve obtained from the ROI positioned in the lesion is 
shown in Figure 2B. T2-weighted image and the ADC map of 
the same patient are shown for comparison in Figures 2C,D. The 
malignant lesion was hypointense compared to the surrounding 
tissue on T2-weighted image, while on DCE image, the lesion was 
hyperintense. The time intensity curve showed a washout pattern, 
which was indicative of malignancy. In addition, on ADC map, 
the lesion was hypointense, suggestive of restricted diffusion.
Differentiation of Malignant, Benign 
lesions, and healthy Breast Tissues
The mean ADC of malignant lesions was significantly 
lower (1.02  ±  0.17  ×  10−3  mm2/s) compared to benign 
(1.57 ± 0.26 × 10−3 mm2/s) and healthy (1.78 ± 0.13 × 10−3 mm2/s) 
breast tissues (Table 2; Figure 1). Also, a significant difference 
in the age-adjusted ADC of malignant compared to benign and 
healthy breast tissues of volunteers was obtained (Table 2). The 
ADC of various histological types of malignant lesions was simi-
lar as shown in Table 3. A comparison of ADC among various 
benign lesions showed that the ADC was significantly lower in 
fibroadenomas compared to fibrocystic with fibroadenoma and 
cystic lesions (P <  0.05; Table 4). Further, the ADC of benign 
ductal epithelial was also significantly lower compared to fibro-
cystic with fibroadenoma and cystic lesions (P < 0.05; Table 4).
Using ROC analysis, a cutoff value of 1.23 × 10−3 mm2/s [sen-
sitivity of 92.5%; specificity of 91.1% and area under the curve 
(AUC) of 0.96] was determined to differentiate malignant from 
benign breast tissues (Table 2).
Furthermore, utility of ADC as an aid in the diagnosis of 
malignancy in patients with indeterminate DCE findings was 
evaluated in 59 patients with malignant lesions. Of these, 49 
lesions showed a Type III washout curve indicating malignancy, 
while 9 showed Type II curve, and 1 patient showed Type I curve, 
suggestive of indeterminate DCE findings (Table  5). However, 
their ADC values were below the cutoff value (1.23 × 10−3 mm2/s). 
Three patients with IDC demonstrated an ADC that was above 
the cutoff value with a Type III curve on DCEMRI, indicating the 
false-negative finding (Table 5).
comparison of aDc, Volume, and age in 
Malignant Tumors classified Based on the 
stage, Menopausal, and hormonal 
receptor status
Significant difference in tumor volume was seen, while there was 
no significant difference in the mean ADC of tumors with dif-
ferent AJCC stages (Table 6). Also, ADC and the tumor volume 
were significantly higher in LABC patients compared to those 
with early breast cancer patients (EBC; P < 0.05; Table 6).
Our data further showed that patients who were negative 
for all receptors, i.e., patients with triple negative (TN) status 
were of younger age, had a larger tumor volume and a higher 
ADC value compared to those with non-triple negative (nTN), 
ER+, and PR+ status. Also, ER− patients showed a larger tumor 
volume and were of younger age group compared to those with 
ER+ status (Table  6). The tumor volume of 13 triple positive 
(TP) patients (positive for all three receptors, i.e., ER+, PR+, 
and HER2+) was significantly lower than the TN patients, while 
there was no significant difference in patients’ age and mean 
ADC value between these two groups. No association was seen 
between ADC, tumor volume, and the menopausal status of 
patients (see Table 6).
DiscUssiOn
Metabolic reprograming is an important area of research that com-
bines numerous aspects of metabolic adaptation associated with 
the cancer proliferation. Cancer cells upregulate their metabolism 
to meet their biosynthetic demands to facilitate the uncontrolled 
cell replication, leading to changes in the tissue characteristics 
and the microenvironment, and these could be monitored using 
DWI. Due to its potential to improve the characterization and 
diagnosis of breast lesions, DWI is increasingly being included in 
breast MRI protocols. The present study investigated its potential 
in the characterization of breast lesions and its association with 
prognostic factors, such as tumor stage and hormonal receptor 
status, in a large cohort of subjects. Our data showed that ADC 
of malignant lesions was significantly lower compared to benign 
lesions and healthy breast tissues of volunteers. Also, the age-
adjusted ADC of healthy breast tissues was significantly higher 
compared to the benign breast tissues. These findings were in line 
with previous studies (29–34). Malignant tumors are character-
ized by high proliferative activity that increases the cell density 
and consequently restricts the diffusion of water molecules result-
ing in a lower ADC value (12, 29, 35). A significant relationship 
FigUre 1 | T2-weighted MR images of (a) a 28-year-old patient with infiltrating ductal carcinoma (IDC); (B) a 25-year-old patient with benign fibroadenoma; and (c) 
a 30-year-old volunteer with healthy breast tissue. The respective DW images are shown in (D–F), while the ADC maps obtained are shown in (g–i).
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has been reported between ADC and the tumor cellularity using 
histology (11, 18, 36, 37).
We found 12 different histological types of malignant lesions 
in our study cohort, which showed similar ADC values. Eight 
patients with IDC had components of DCIS, and the mean ADC 
of these lesions was similar to that of IDC lesions. This might be 
due to increased endoductal cellular density. Several studies have 
reported higher ADC in DCIS compared to IDC lesions (16, 17, 
24, 25, 31, 38). Elucidation of DCIS tumors using DWI has not 
been consistent due to interspersed distribution of cancer cells 
and healthy breast parenchyma (17). Medullary invasive cancer, 
a rare low grade tumor, also showed a low ADC similar to IDC 
lesions (16, 18, 31). Further, six patients presented with mucinous 
carcinoma with IDC, and the mean ADC was also similar to that 
seen for IDC lesions. Few studies have reported a higher ADC for 
mucinous carcinoma compared to IDC, which has been ascribed 
to the presence of colloidal mucin content (18) and the relative 
volume of the mucin and the cellularity of lesion (17, 35). In our 
study, patients with invasive lobular carcinoma (n = 3), Paget’s 
disease (n = 1), fibrous stroma (n = 1), and phyllodes (n = 1) 
also showed a lower ADC, similar to that seen for IDC lesions. 
However, the number of patients in these histological types was 
less to draw any definitive conclusion.
Additionally, the ADC values were compared among the 
various histological types of benign lesions. Mean ADC was 
statistically lower in fibroadenomas and benign ductal epithelial 
lesions compared to fibrocystic with fibroadenoma and cystic 
lesions (16, 29). Cystic lesions represent a pouch filled with fluid 
and proteins, and therefore have less restricted water diffusion 
compared to that seen in fibroadenomas, which are solid lesions 
with relatively more cellularity. In literature, lower ADC in 
fibroadenoma lesions has been reported, which was attributed to 
the presence of fibrous component (16, 39, 40), while in our study, 
only one fibroadenoma and one fibrocystic with fibroadenoma 
lesion showed a low ADC value. Benign phyllodes, mastitis, and 
benign proliferative lesions showed higher ADC characteristic of 
benign breast disease. In contrary, a low ADC value similar to 
malignant tumors has been reported for mastitis (17).
TaBle 2 | Distribution of mean aDc in malignant and benign breast 
lesions, and healthy breast tissue of volunteers and cutoff aDc values 
using rOc analysis.
Malignant  
(n = 259)
Benign  
(n = 67)
healthy volunteers 
(n = 54)
ADC (×10−3 mm2/s) 
(mean ± SD)
1.02 ± 0.17 1.57 ± 0.26* 1.78 ± 0.13*#
ancOVa
ADC (×10−3 mm2/s) 1.06 (1.04, 1.09) 1.61 (1.55, 1.68)* 1.83 (1.76, 1.89)*#
Adjusted mean  
(95% CI)@
Malignant vs. 
benign
Malignant vs. 
healthy volunteers
Benign vs. healthy 
volunteers
Difference between 
means (95% CI)
0.55 (0.55, 0.56) 0.76 (0.76, 0.77) 0.21 (0.21, 0.22)
rOc analysis and aDc cutoff
Malignant vs. 
benign
1.23 (sensitivity 92.5%; specificity 
91.1%; AUC 0.96)
Malignant vs. 
healthy
1.43 (sensitivity 100%; specificity 
98.1%; AUC 0.99)
Healthy vs. 
benign
1.69 (sensitivity 75.9%; specificity 
74.6%; AUC 0.79)
@Adjusted for age.
*Denotes P < 0.05 between benign vs. malignant; malignant vs. healthy volunteers.
#Denotes P < 0.05 between benign vs. healthy volunteers.
FigUre 2 | (a) T1-axial DCEMR image of a 56-year-old patient with infiltrating ductal carcinoma (IDC); (B) Type III dynamic curve with washout pattern from the ROI 
shown in the lesion; (c) T2-weighted fat-saturated axial image; and (D) the ADC map of the same patient.
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With the availability of ADC values from a large cohort of 
malignant, benign, and healthy breast tissues, we determined 
a cutoff value of mean ADC using ROC curves to predict 
malignancy. A cutoff value of 1.23 × 10−3 mm2/s was obtained to 
differentiate malignant from benign disease, which was similar 
to that reported previously (20, 30, 31, 41). However, a few 
studies have reported a higher cutoff, which may be due to the 
variability in experimental parameters used such as low b values 
(14, 16). Further, a meta-analysis of 13 studies that included 615 
malignant and 349 benign lesions reported a sensitivity of 84% 
and a specificity of 79% with area under the curve (AUC) of 0.90 
for ADC to differentiate between benign and malignant lesions. 
The sensitivity and the specificity calculated in this meta-analysis 
were lower than that seen in the present study (32). This was 
attributed to the variation in methodology and the b values used 
across studies (32). At low b values (<200 s/mm2), the effect of 
perfusion is more, while at high b values, pure diffusion com-
ponent would dominate the measured signal (42). The b values 
used by us emphasize on minimizing the perfusion and T2 
shine-through effect. Also, a cutoff value of 1.43 × 10−3 mm2/s 
(sensitivity 100%; specificity 98.1%) was obtained to discrimi-
nate malignant from healthy breast tissue, which was similar to 
our earlier observation (20).
TaBle 3 | Distribution of mean aDc, volume, and age in various histological types of breast cancer patients (n = 209).
Malignant lesions (histological types) number (n) age (years) (mean ± sD) aDc (×10−3 mm2/s) (mean ± sD) Volume (cm3) (mean ± sD)
IDC 182 45.4 ± 10.2 1.00 ± 0.16 78.5 ± 89.7
IDC + DCIS 8 43.6 ± 12.9 1.05 ± 0.15 41.3 ± 25.9
IDC + mucinous (or colloid) 6 42.2 ± 19.2 1.05 ± 0.17 59.3 ± 64.0
Papillary 1 53 1.01 29.0
Lobular 3 53.6 ± 7.5 0.96 ± 0.09 73.4 ± 76.7
Ductal adenocarcinoma 2 51.5 ± 9.9 0.91 ± 0.19 42.9 ± 28.2
DCIS + cribriform 2 35.4 ± 14.4 0.97 31.9 ± 19.6
Neuroendocrine 1 65 0.99 15.5
Fibrous stroma 1 53 0.94 29.1
Malignant phyllodes 1 50 1.02 23.5
Paget disease 1 40 0.99 7.2
Medullary 1 57 1.08 30.6
Total 209
TaBle 4 | Distribution of mean aDc values and age in various 
histological types of benign breast lesions.
Benign lesions number (n) age  
(mean ± sD)
aDc (×10−3 mm2/s) 
(mean ± sD)
Fibroadenomas 
(FA)
33 29.1 ± 10.1 1.48 ± 0.17*
Benign ductal 
epithelial
8 30.9 ± 7.5 1.42 ± 0.18@
Benign phyllodes 8 31.3 ± 12.7 1.73 ± 0.25
Fibrocystic with FA 8 29.8 ± 4.4 1.80 ± 0.31*,@
Cyst 6 33.5 ± 11.5 1.80 ± 0.30*,@
Sclerosing 
adenosis
1 29 1.18
Mastitis 1 34 1.44
Fibroepithelial 1 32 1.66
Benign proliferative 1 20 1.79
Total 67
*P < 0.05 between fibroadenoma and fibrocystic disease with FA and cyst.
@P < 0.05 between benign ductal epithelial cells and fibrocystic disease with FA and cyst.
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Further, we compared the DCEMRI kinetics and the ADC 
data in detecting malignancy in 59 breast cancer patients. Of the 
59 lesions in these patients, 49 showed washout curve (Type III), 
which was characteristic of malignancy, while 10 showed inde-
terminate curves [Type I (n = 1) and Type II (n = 9)]. However, 
the ADC values obtained in these 10 lesions were below the cutoff 
value (1.23 × 10−3 mm2/s), indicative of positive for malignancy. 
Of these 10 lesions, 8 were IDC, 1 was DCIS + cribriform, and the 
other 1 was papilloma. Kuhl et al. also have reported DCE kinetics 
to be inconsistent for diagnosis of DCIS lesions (8). Thus, our 
findings demonstrated that addition of DWI increases the sensi-
tivity and the diagnostic accuracy of breast cancer (17, 26, 30, 43). 
Also, DWI has a significant advantage over DCEMRI as diffusion 
is highly sensitive to changes in the cellular environment, and 
there is no need to use contrast agent (17). Additionally, DWI has 
a short scan time. It has also been reported that DWI of breast 
in combination with T2-weighted imaging has the potential to 
improve the specificity of breast cancer diagnosis (17). However 
in our study, three IDC patients with AJCC stage III A and with 
Type III curve showed an ADC value which was above the cutoff, 
which may be attributed to the intermingling necrotic cores seen 
in such large sized tumors (44).
Further, the association among ADC, age, hormonal receptor 
status, tumor volume, stage, and the menopausal status of patients 
was investigated. Tumor volume and ADC showed no association 
with the menopausal status. The tumor volume was significantly 
different among various AJCC stage tumors, while ADC was not 
significantly different. LABC patients had a higher ADC and a 
larger tumor volume compared to EBC patients. Correlation 
between ADC and the histologically determined tumor size has 
been reported (36). Higher ADC in large sized tumors may be 
related to the formation of intermingling necrotic regions due to 
non-uniform supply of nutrients in fast growing tumors. It is well 
recognized that by upregulating their metabolism, cancer cells 
eventually grow into a tumor mass, and further growth requires 
abundance of nutrients to support biosynthesis of nucleic acids, 
proteins, and lipids essential for replication. However, the nutri-
ent supply for cancer cells varies across the tumor mass, and the 
cells on the surface of the tumor may get more nutrients and 
continue replicating, but cells at the central regions may die due to 
limited availability of nutrients (45, 46). Further, the gradients in 
nutrient availability in different regions of the tumor are an out-
come of altered metabolic pathways such as glucose metabolism, 
glutamine synthesis, and oxygen availability (47). Thus, there will 
be lack of uniform availability of nutrient material affecting the 
metabolic activity and the viability of tumor cells. This eventually 
would lead to a heterogeneous mixture of dead, quiescent, and 
mitotic cells in large sized tumors, which is reflected in parameters 
such as ADC and tCho concentration determined by functional 
MR techniques. It was documented that ADC reflects the relative 
necrotic content of tumors as relative volume fraction of water in 
the extracellular space is increased due to cell death, leading to 
higher ADC (48). Further, EBC had a higher tCho concentration 
compared to LABC, indicating more necrotic cores in LABC 
(49). In an earlier study, ADC was used to delineate necrotic and 
viable regions using DWI in patients who cannot afford the cost 
of contrast (44). In the calculation of ADC, the visible hyperin-
tense necrotic areas were avoided; however, there is a possibility 
that intermingling microsized necrotic regions might have been 
included in the ROIs, especially in large tumors, which might 
have led to higher ADC seen in LABC patients.
Triple-negative cancers showed a higher ADC compared to 
nTN cancers, which is in agreement with the findings of Youk et al. 
TaBle 6 | Distribution of mean aDc, age, and volume in various subgroups of breast cancer patients based on tumor stage, menopausal, and hormonal 
biomarker status.
groups number (n) age (years) (mean ± sD) aDc (×10−3 mm2/s) (mean ± sD) Volume (cm3) (mean ± sD)
Premenopausal (Pre) 119 36.4 ± 5.9§ 1.02 ± 0.18 78.50 ± 80.60
Postmenopausal (Post) 140 53.0 ± 7.5§ 1.02 ± 0.17 70.45 ± 87.33
EBC 52 46.7 ± 11.9 0.98 ± 0.18@ 17.67 ± 19.12$
LABC 207 45.0 ± 10.4 1.03 ± 0.17@ 88.17 ± 88.26$
Stage IIA 52 46.7 ± 11.9 0.98 ± 0.18 17.67 ± 19.12*
Stage IIB 49 43.8 ± 10.4 0.98 ± 0.12 49.34 ± 51.74*
Stage IIIA 45 46.0 ± 9.2 1.05 ± 0.20 82.23 ± 70.04*
Stage III (B + C) 113 45.2 ± 10.9 1.04 ± 0.17 107.21 ± 101.02*
HER2+ 56 44.7 ± 10.3 1.03 ± 0.16 94.60 ± 93.27
HER2− 84 45.1 ± 11.1 1.02 ± 0.15 84.47 ± 83.74
ER+ 93 47.8 ± 10.8£ 0.99 ± 0.14 54.57 ± 50.62&
ER− 92 43.4 ± 10.5£ 1.02 ± 0.16 97.72 ± 104.94&
PR+ 82 46.9 ± 11.4 1.00 ± 0.14 64.81 ± 61.74†
PR− 100 44.4 ± 10.2 1.02 ± 0.16 86.71 ± 100.29†
Triple-negative (TN) 26 40.9 ± 9.9+ 1.07 ± 0.19# 111.21 ± 116.34¥
Triple-positive (TP) 13 42.8 ± 12.2 1.01 ± 0.16 61.19 ± 69.51¥
Non-triple-negative (nTN) 155 46.4 ± 10.8+ 1.00 ± 0.14# 69.21 ± 74.06¥
§,£,+Age P < 0.05: between §pre vs. post; £ER+ vs. ER−; +TN vs. nTN.
@,#ADC P < 0.05: between @EBC vs. LABC; #TN vs. nTN.
$,*,&,†,¥Volume P < 0.05: between $EBC vs. LABC; *stages IIA, IIB, IIIA, and III (B + C); &ER+ vs. ER−; †PR+ vs. PR−; ¥TN vs. nTN and TN vs. TP.
*Significant difference in tumor volume of different tumor stages.
TaBle 5 | aDc value, histology, stage, volume, and BiraDs of breast cancer patients who showed Type i or ii curve on DceMri and those patients 
who showed aDc above the cutoff value.
Patient no. histology curve type aDc (×10−3 mm2/s) Tumor volume (cm3) aJcc stage BiraDs
1. IDC Type I 1.09 77.92 IIB 5
2. IDC Type II 1.16 117.6 IIB 5
3. DCIS + cribriform Type II 0.97 45.85 IIB 5
4. IDC Type II 0.95 2.38 IIIA 4b
5. IDC Type II 0.98 78.34 IIB 4
6. IDC Type II 1.08 5.26 IIIA 6
7. Papillary carcinoma Type II 1.02 29.06 IIB 5
8. IDC Type II 0.98 59.82 IIA 3
9. IDC Type II 0.97 29.35 IIIB + C 4
10. IDC Type II 0.92 44.92 IIIA 4
Breast cancer patients with Type III 
curve but mean ADC above cutoff
1. IDC Type III 1.31 54.52 IIIA 5
2. IDC Type III 1.24 41.43 IIIA 5
3. IDC Type III 1.28 160.27 IIIA 5
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(23). Also, TN cancers had a larger tumor volume compared to 
nTN cancers due to aggressive and high proliferative activity (23). 
It has been established that metabolic reprograming of both cata-
bolic and anabolic pathways occurs to support the survival and 
high proliferation of cancer cells (47). This metabolic demand is 
fulfilled by the overexpression of several enzymes such as pyruvate 
kinase and glutamine fructose 6-phosphate transaminase (50). 
Higher glutamine utilization compared to other breast cancer 
types has been reported in TN cancers, indicating higher energy 
demand for cell proliferation (51). Further, lipid reprograming 
with upregulation of genes involved in lipid biosynthesis has also 
been reported to be an important hallmark of cancer develop-
ment and progression (52). However, TN cancers had lower 
concentration of tCho (membrane metabolites) compared to 
that seen in nTN and TP cancers (51). This observation indicates 
the presence of intermingling necrotic cores in large sized TN 
cancers and the molecular heterogeneity of breast lesions (51). 
It was reported that 56% of TN cancers showed intratumoral 
necrosis (23) and frequent rim enhancement, suggestive of high 
angiogenesis in the periphery of the tumor, central necrosis, and 
fibrosis (53). Additionally, the TN group consisted of younger and 
premenopausal women as reported in literature (54, 55).
Further, our results revealed that ER− cancers had a larger vol-
ume and were of younger age compared to ER+ cancers (56, 57). 
Higher proliferative activity (58) and higher micro-vessel density 
associated with a larger volume (59) has been documented in 
ER− cancers. Studies have reported lower ADC in ER+ compared 
to ER− cancers (25, 42, 56, 60), while the value was similar for 
these cancers in our study. PR+ showed a lower ADC compared 
to PR− cancers (25, 61), while a higher ADC has been reported 
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in HER2+ cancers (53, 56, 60, 62). In the present study, there was 
no significant difference in ADC of HER2+ and PR+ compared 
to HER2− and PR− cancers. Many studies showed no associa-
tion of ADC with the hormonal receptor status (22, 24, 63, 64). 
Thus, variable findings are seen in literature on the association of 
hormonal receptor status with the ADC values in breast cancer 
patients.
Several factors may be responsible for such variable find-
ings in the ADC values and its association with the hormonal 
status of breast cancer patients. First, it may represent the 
heterogeneous nature of breast cancers, which may be related to 
the biological behavior of cancers in relation to the expression 
of various receptors. Inhibition of angiogenic pathway due to 
estrogen hormone has been reported in ER+ cancers, which may 
decrease the perfusion in ER+ cancers (22, 65). Recently, Cho 
et al. reported that higher ADC in ER− cancers may be related to 
the tumor vascularity and perfusion using intravoxel incoherent 
motion imaging (42). Hyder et al. have shown that progesterone 
may increase the angiogenesis through regulation of VEGF in 
breast cancer (66). Association between angiogenesis and HER2 
expression has also been described (67, 68). These findings 
indicated that positive ER expression was associated with the 
inhibition of angiogenesis, while positive PR and HER2 expres-
sion was associated with the enhancement of angiogenesis. Thus, 
there is a need to take into account the expression status of all 
the three receptors while interpreting the ADC and the tumor 
volume data.
Additionally, the variability in results across studies might 
also be due to the differences in the tumor size and variations 
in terms of experimental procedures used such as selection of 
b-value, choice of imaging sequence, and the method used for 
measurement of ADC. In our study, the mean ADC calculation 
was carried out by drawing small circular ROIs encompassing 
the entire visible tumor on a slice that showed the largest tumor 
area but avoiding necrotic areas. However, most studies in the 
literature have drawn either single or only few ROIs and have 
reported mean ADC (24, 60, 62). The methodology adopted 
by us, though time consuming, may provide a more accurate 
determination of the ADC and tumor heterogeneity. Arponent 
et al. also demonstrated that ADC measurements using small ROI 
were more accurate than whole region ROI (61).
In spite of the clinical potential of DWI, the study has some 
limitations. First, the sample size was small for some histological 
types to arrive at definitive conclusions and thus warrant further 
investigation in a large cohort. Second, multicenter studies with 
standardized DWI protocol across various laboratories with an 
appropriate algorithm are required for consistent results in ADC 
measurement. Third, due to poor socioeconomic status, DCEMRI 
could not be carried out in all patients.
cOnclUsiOn
The present study on a relatively large cohort of subjects demonstrated 
that a low ADC value is indicative of malignancy. The sensitivity and 
specificity calculated from the present data indicated that ADC is a 
sensitive parameter for the differentiation of malignant, benign, and 
healthy breast tissues in a short scan time. Further, the changes seen 
in ADC with various hormonal receptors show its dependence on the 
biological features of different tumor subtypes, stage, etc. Moreover, the 
functional MR imaging techniques, such as quantitative DWI, provide 
an insight into metabolic reprograming and the heterogeneity of breast 
cancers. Also, the MR imaging features of various molecular subtypes 
of breast cancer may aid in appropriate incorporation of non-invasive 
approaches for molecular characterization of breast cancer, which 
would be useful in treatment planning and patient management.
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